Interim report January 1 – March 31, 2024
FIRST QUARTER (JANUARY – MARCH 2024)
- Oder intake SEK 238.5 M (206.6)
- Net sales SEK 257.2 M (230.2)
- Operating profit SEK 45.8 M (23.7)
- Profit after tax SEK 36.7 M (17.6)
- Earnings per share before/after dilution SEK 1.07 (0.51)
- Cash flow SEK 87.9 M (84.5)
- Order backlog SEK 1,848.0 M (1,903.3) MSEK at the end of the period
SIGNIFICANT EVENTS DURING THE FIRTS QUARTER
- RayStation in more than 1,000 radiotherapy centers worldwide.
- The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch.
- RaySearch acquires the product DrugLog from Pharmacolog.
- World leading carbon ion center QST in Chiba, Japan, selects RayStation.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
- Raigmore Hospital in Scotland selects RayCare.
- RaySearch and C-RAD signed collaboration agreement.
- RayCare has been certified to be interoperable with Varian TrueBeam.
WEBCAST
CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch’s interim report for January-March 2024 at a webcast to be held in English on Friday, May 17, 2024 at 10:00 a.m. CET.
Link to webcast: RaySearch Q1, 2024
You can also join the webcast by phone:
Sverige: +46 (0) 8 505 100 31
UK: +44 (0) 207 107 06 13
US: +1 (1) 631 570 56 13
The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on May 17, 2024 at. 7:45 a.m. CET.
